AzTrials
AzTrials

Acute Respiratory Distress SyndromeOPTI-PEEPNCT07741916

Comparison of Different PEEP Strategies in Moderate-to-Severe ARDS Based on Various Bedside Assessment Tools

A study testing Ventilation at different levels of PEP including a test involving a gradual decrease in PEP. in people with Acute Respiratory Distress Syndrome, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Many patients admitted to the intensive care unit (ICU) for a severe lung disease called acute respiratory distress syndrome (ARDS) require mechanical ventilation and positive end-expiratory pressure (PEEP) to improve their oxygenation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Respiratory Distress Syndrome
What is being tested?
Ventilation at different levels of PEP including a test involving a gradual decrease in PEP.
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteFrance
Study dates
Sep 2026to Jan 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients on invasive mechanical ventilation
  • With moderate-to-severe ARDS :
  • Bilateral findings on chest X-ray
  • PaO₂/FiO₂ ratio <200 with PEEP ≥+5 cmH₂O
  • No evidence of cardiogenic pulmonary overload
  • Patients without inspiratory effort (curare administration not required)
Show all 9Show fewer
  • Patient already fitted with an esophageal pressure probe
  • Patient already fitted with a thoracic impedance belt
  • No objection from the patient or a family member to the processing of their clinical data

Who cannot join

  • Protected individuals, namely:
  • Individuals receiving enhanced protection, namely minors
  • Individuals deprived of their liberty by a judicial or administrative decision
  • Pregnant and breastfeeding women
  • Individuals residing in a health or social care facility
  • Adults under legal guardianship
Show all 15Show fewer
  • Patients with a do-not-resuscitate order or a decision to limit care
  • Patients with a pacemaker or an implantable cardioverter-defibrillator
  • Acute cor pulmonale
  • Pneumothorax or ongoing pleural/thoracic drainage
  • Patients in the prone position
  • Hemodynamic instability
  • An increase of >30% in the norepinephrine dosage over the past 6 hours
  • Norepinephrine dosage > 0.5 µg/kg/min
  • Patients on veno-venous ECMO

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Clément Saccheri, MD contact

+33 4 92 03 55 10

saccheri.c@chu-nice.fr

France1 site
  • CHU de Nice

    Nice

    Clément Saccheri, MD, +33 4 92 03 55 10, saccheri.c@chu-nice.fr

    Clément Saccheri, MD

Other trials in France

About this study

Official title: Comparison of Different PEEP Strategies in Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS) Based on Various Bedside Assessment Tools

Many patients admitted to the intensive care unit (ICU) for a severe lung disease called acute respiratory distress syndrome (ARDS) require mechanical ventilation and positive end-expiratory pressure (PEEP) to improve their oxygenation. Ventilator settings-and particularly the level of PEEP-are critical in the management of these patients. In fact, inappropriate ventilator settings can lead to a worsening of the patients' lung disease or compromise their hemodynamic status.

PEEP is a pressure maintained by the ventilator during the patient's exhalation to keep the alveoli open throughout the respiratory cycle. When PEEP is increased, if many alveoli open, this is called alveolar recruitment, which is the expected beneficial effect. However, in some patients, increasing PEEP can cause already-open alveoli to become overdistended without opening new alveoli; this is known as pulmonary overdistension. This phenomenon of overdistension will worsen the patient's pulmonary condition and may also lead to hemodynamic deterioration. To date, numerous techniques have been proposed for determining the optimal PEP level (alveolar recruitment without pulmonary overdistension) in these patients, but none can be recommended as the gold standard. The objective of our study is therefore to compare the various existing methods for determining the optimal PEEP level, in order to determine whether these methods are interchangeable and which would be the best method to use to optimize the care of these patients.

To this end, the investigators plan to conduct a prospective, observational, multicenter study in the Intensive Care Units of the Nice University Hospital and the European Hospital of Marseille. Patients on mechanical ventilation for ARDS will be included in the study, and medical and laboratory data from the electronic medical records obtained during the various PEEP measurements to determine the optimal PEEP will be analyzed.

Being tested
Ventilation at different levels of PEP including a test involving a gradual decrease in PEP.
Keywords
Acute Respiratory Distress Syndrome, positive end expiratory pression
Medical subject headings
Respiratory Distress Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ventilation at different levels of PEP including a test involving a gradual decrease in PEP.Dietary supplement

    Initial PEEP level will be set according to the PEEP/FiO2 table. The PEEP level will then be adjusted to achieve a plateau pressure of 28-30 cmH₂O. After 10 minutes, various hemodynamic and respiratory variables will be recorded, and an arterial blood gas analysis will be performed to assess the patient's respiratory mechanics and oxygenation. Next, the airway opening pressure will be measured, and the patient's recruitment potential will be assessed by calculating the R/I ratio through a sudden reduction in PEP from 15 cmH₂O to 5 cmH₂O over a single respiratory cycle. Following this, PEEP will be raised back to the initial level for at least 5 minutes and then gradually reduced in 2 cmH₂O increments every 2 minutes until reaching the AOP level or a PEEP level of 5 cmH₂O. In total, the optimal PEP level will be determined using six different techniques, allowing the clinician to obtain six optimal PEP values and thus best customize the ventilator settings for each patient.

Study groups in NCT07741916
Study groupRoleWhat they receive
Study populationExperimentalNot described
Receives: Dietary Supplement: Ventilation at different levels of PEP including a test involving a gradual decrease in PEP.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Level of positive end expiratory pressure

    The primary outcome measure will be the optimal level of positive end expiratory pressure achieved with each of the methods used.

    The measurement of differents optimal level of positive end expiratory pressure will be determined after the positive end expiratory pressure reduction procedure.

    Measured: at baseline

Secondary outcomes (2)
  1. Minimale driving pressure

    Minimale driving pressure will be assessed at various optimal positive end expiratory pressure levels according with each of the methods used.

    Determining the minimum driving pressure of differents optimal level of positive end expiratory pressure will be determined after the positive end expiratory pressure reduction procedure

    Measured: at baseline

  2. Maximum pulmonary compliance

    Maximum pulmonary compliance will be assessed at various optimal positive end expiratory pressure levels according with each of the methods used.

    Determining the maximum pulmonary compliance of differents optimal level of positive end expiratory pressure will be determined after the positive end expiratory pressure reduction procedure

    Measured: at baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2026
  2. Study startSep 2026 (estimated)
  3. Primary completionSep 2029 (estimated)
  4. Study completionJan 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07741916
Sponsor's protocol ID
25-PP-17
Acronym
OPTI-PEEP
Status last verified
Jul 2026
First submitted
23 Jul 2026
Last updated
3 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Ventilation at different levels of PEP including a test involving a gradual decrease in PEP. in people with Acute Respiratory Distress Syndrome, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Clément Saccheri, MD (+33 4 92 03 55 10, saccheri.c@chu-nice.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Level of positive end expiratory pressure (time frame: at baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in